Shopping Cart
- Remove All
- Your shopping cart is currently empty
NLRP3-IN-41 administered at doses of 40 and 80 mg/kg through intragastric (i.g.) delivery over a span of 10 days, successfully alleviated the symptoms of colitis induced by DSS in both C57BL/6 and ICR mice.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | NLRP3-IN-41 administered at doses of 40 and 80 mg/kg through intragastric (i.g.) delivery over a span of 10 days, successfully alleviated the symptoms of colitis induced by DSS in both C57BL/6 and ICR mice. |
In vitro | NLRP3-IN-41 (5-15 μM, 24 h) effectively inhibits the induction of IL-1β by LPS (100 ng/mL) and ATP (5 mM) in THP-M and also suppresses AIM2 and NLRC4 inflammasomes. |
In vivo | NLRP3-IN-41 administered at doses of 40 and 80 mg/kg through intragastric (i.g.) delivery over a span of 10 days, successfully alleviated the symptoms of colitis induced by DSS in both C57BL/6 and ICR mice. |
Molecular Weight | 442.55 |
Formula | C22H22N2O4S2 |
Cas No. | 1209698-02-1 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.